No causative genes or inheritance patterns are certified in this packet for atypical teratoid rhabdoid tumor. The tumor occurs predominantly in early childhood. Onset data are not certified in this packet.

ATRT is diagnosed as a malignant CNS neoplasm. Specific diagnostic criteria, imaging protocols, and pathological confirmation approaches are not certified in detail in this packet.

No foundational therapies or approved treatments for ATRT are certified in this packet. Active clinical trials include: NCT07087002 (Phase 1, Stanford University, recruiting) evaluating GPC2-CAR T cell therapy for relapsed or refractory CNS tumors; NCT02114229 (Phase 2, St. Jude Children's Research Hospital, active not recruiting) studying alisertib for rhabdoid tumors; NCT06622941 (Phase 2, Ono Pharmaceutical, recruiting) examining ONO-4538 in rhabdoid tumors; NCT07390539 (Phase 1, recruiting) evaluating B7-H3-directed CAR-T cell therapy in CNS neoplasms; and NCT06942039 (Early Phase 1, C17 Council, recruiting) piloting intrathecal topotecan with maintenance chemotherapy.

Prognosis data for atypical teratoid rhabdoid tumor are not certified in this packet.

Ten active or recruiting clinical trials are documented for ATRT in this packet, spanning Phase 1 through Phase 2 designs. Investigation areas include CAR-T cell immunotherapies targeting GPC2 and B7-H3, MEK pathway inhibitors, checkpoint inhibitors (NCT05286801, tiragolumab and atezolizumab), and locoregional CNS delivery approaches. NCT03155620 (NCI, Phase 2) applies targeted therapy directed by genetic testing.